Psilocybin for Major Depressive Disorder: Study Design and Findings

This chapter explores the first large FDA phase 2B study of psilocybin for major depression, describing the study design and its unique aspects. It discusses the process of administering psilocybin, the main findings of the study, including the sustained anti-depressant response, and the safety profile of psilocybin. The chapter also highlights the potential side effects of psilocybin and the positive implications of achieving a sustained anti-depressant response with just a single treatment.